New Results

Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies

Daichi Yamasoba, Yusuke Kosugi, Izumi Kimura, Shigeru Fujita, Keiya Uriu, Jumpei Ito, Kei Sato, The Genotype to Phenotype Japan (G2P-Japan) Consortium
doi: https://doi.org/10.1101/2022.05.03.490409

Article Information

doi 
https://doi.org/10.1101/2022.05.03.490409
History 
  • May 3, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Daichi Yamasoba, Ph.D.1,2,#,
  2. Yusuke Kosugi, M.S.1,#,
  3. Izumi Kimura, Ph.D.1,#,
  4. Shigeru Fujita, D.V.M.1,
  5. Keiya Uriu, M.S.1,
  6. Jumpei Ito, D.V.M., Ph.D.1,
  7. Kei Sato, Ph.D.1,*,
  8. The Genotype to Phenotype Japan (G2P-Japan) Consortium
  1. 1The University of Tokyo, Tokyo, Japan
  2. 2Kobe University, Hyogo, Japan
  1. ↵*Correspondence: KeiSato{at}g.ecc.u-tokyo.ac.jp (Kei Sato)

  1. ↵# Dr. Yamasoba, Mr. Kosugi and Dr. Kimura contributed equally to this letter.

Back to top
Posted May 03, 2022.
Download PDF

Supplementary Material

Email
Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies
Daichi Yamasoba, Yusuke Kosugi, Izumi Kimura, Shigeru Fujita, Keiya Uriu, Jumpei Ito, Kei Sato, The Genotype to Phenotype Japan (G2P-Japan) Consortium
bioRxiv 2022.05.03.490409; doi: https://doi.org/10.1101/2022.05.03.490409
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area